evaluation of therapeutic effect of rifampin for acute central serous chorioretinopathy
نویسندگان
چکیده
purpose: to evaluate the beneficial effects of rifampin for the treatment of central serous chorioretinopathy (cscr). methods: in this non-randomized clinical trial, 39 patients with acute cscr (<2 weeks) were enrolled. initially, complete visual examinations including determination of best spectacle-corrected visual acuity (bscva) using snellen chart; anterior and posterior segment examination was performed. fundus fluorescein angiography (ffa) and ocular coherence tomography (oct) were also performed to confirm the diagnosis. twenty-three patients were treated with 600 mg rifampin per day for a maximum of 4-6 weeks (treatment group) and 17 patients did not receive any treatment (control group). the patients were examined post treatment at weeks 2, 4 & 6. at each follow-up examination bcva and fundoscopy were performed. if no macular edema was observed in fundoscopy, oct was performed; otherwise oct was performed at the end of 4th-6th week. primary objective was reduction in macular thickness (mt) and secondary objective was the bscva. results: mean age of patients was 38.5±6.7 years; 37.7±6.2 years in the treatment group and 39.7±7.3 years in the control group (p>0.05). 76.9% of patients were male. mean mt reduced from 339.9±44.36 µm at the beginning of treatment to 297.4±29.09 µm at the final visit (12.58% reduction, p<0.001). in the control group, the figures were 310.06±20.31 and 296.71±17.22 µm, respectively (4.3% reduction, (p<0.003). the treatment group demonstrated more reduction in mt (p<0.018). mean bscva was 0.2±0.18 and 0.6±0.34 sv before and after treatment respectively (p<0.0001) in the treatment group and 0.2±0.1 and 0.37±0.35 sv, respectively (p<0.024) in the control group. the difference in bscva between the two groups was significant (p=0.055). macula was dry in 45.5% of the treatment group and 29.4% of the control group at the end of study (or=2 ci95%, 0.52-7.6, p=0.307). all the patients with dry macula at the end of study in the treatment group were followed for 9 months and no recurrence of the lesion was found. conclusion: rifampin has beneficial effects in the treatment of acute cscr. these early findings suggest a novel treatment of cscr and warranted further study.
منابع مشابه
Acute Central Serous Chorioretinopathy
PURPOSE To evaluate the influence of clinical and multimodal imaging parameters on the duration of acute central serous chorioretinopathy (CSCR) episodes. METHODS Consecutive patients with first, treatment-naïve central serous chorioretinopathy episodes presenting within 20 days of symptoms onset were prospectively included. They were reevaluated 15 days to 20 days later, followed by monthly ...
متن کاملAtypical Central Serous Chorioretinopathy
Bullous central serous chorioretinopathy (CSCR) is a rare variant of CSCR characterized by severe serous retinal detachment which especially involves the inferior quadrants. Corticosteroid therapy administered for systemic or ocular misdiagnoses may induce and exacerbate CSCR. The purpose of this study was to report diagnosis and treatment results of an unusual case of bullous CSCR induced by s...
متن کاملCentral serous chorioretinopathy.
BACKGROUND Central serous chorioretinopathy is a condition typically affecting young adults between 25 and 50 years of age. It is predominating in type A personality trait men. Central serous chorioretinopathy is defined clinically as a detachment of the sensory retina that is commonly unilateral but can also be bilateral. Laser photocoagulation has been used widely with central serous choriore...
متن کاملCentral serous chorioretinopathy.
The pathogenesis of central serous chorioretinopathy (CSC) is still not fully understood. The involvement of corticosteroids is undisputed, although their exact role has not been clarified; other parts of the underlying mechanism of CSC have been mainly elucidated by imaging techniques such as fluorescein and indocyanine green angiography. Even though most cases of CSC are self-limiting, severe...
متن کاملTopical Nepafenac in Treatment of Acute Central Serous Chorioretinopathy
This study had been performed to investigate the anatomic and functional outcomes of nepafenac 0.1% therapy in acute central serous chorioretinopathy (CSC). The medical records of 30 patients with acute CSC were reviewed for a total of 31 eye charts. Seventeen eye records of 16 patients who were treated with topical nepafenac 0.1% three times daily for four weeks and continued until complete re...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
بیناجلد ۱۹، شماره ۱، صفحات ۴۶-۵۱
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023